HC Wainwright Boosts Earnings Estimates for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Analysts at HC Wainwright raised their Q2 2025 earnings per share estimates for shares of BridgeBio Pharma in a report issued on Monday, June 9th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.87) per share for the quarter, up from their prior forecast of ($1.08). HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.44) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($2.10) EPS.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.12. The company had revenue of $36.74 million for the quarter, compared to analysts’ expectations of $57.14 million. The company’s revenue for the quarter was down 44.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) earnings per share.

BBIO has been the subject of several other reports. Citigroup lifted their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday, February 21st. JPMorgan Chase & Co. upped their price target on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, March 24th. Wall Street Zen raised BridgeBio Pharma from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Scotiabank boosted their price objective on shares of BridgeBio Pharma from $52.00 to $55.00 and gave the company a “sector outperform” rating in a research report on Wednesday, April 30th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.36.

BridgeBio Pharma Stock Performance

NASDAQ BBIO opened at $40.09 on Wednesday. The business’s 50 day moving average price is $34.76 and its 200-day moving average price is $32.87. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $40.40. The company has a market cap of $7.61 billion, a P/E ratio of -14.07 and a beta of 1.10.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ironwood Investment Management LLC increased its holdings in shares of BridgeBio Pharma by 0.5% in the fourth quarter. Ironwood Investment Management LLC now owns 63,157 shares of the company’s stock valued at $1,733,000 after purchasing an additional 338 shares during the period. GAMMA Investing LLC lifted its holdings in shares of BridgeBio Pharma by 71.0% during the first quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after purchasing an additional 382 shares during the period. Xponance Inc. boosted its position in BridgeBio Pharma by 3.8% in the first quarter. Xponance Inc. now owns 10,474 shares of the company’s stock valued at $362,000 after buying an additional 385 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in BridgeBio Pharma by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company’s stock worth $404,000 after buying an additional 466 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its holdings in BridgeBio Pharma by 85.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after buying an additional 472 shares during the period. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Insider Activity

In other news, CEO Neil Kumar sold 75,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $36.87, for a total transaction of $2,765,250.00. Following the completion of the sale, the chief executive officer now directly owns 4,948,447 shares in the company, valued at approximately $182,449,240.89. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the business’s stock in a transaction on Monday, May 12th. The shares were sold at an average price of $34.20, for a total transaction of $205,200,000.00. Following the sale, the insider now directly owns 13,260,971 shares in the company, valued at $453,525,208.20. This trade represents a 31.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,392,182 shares of company stock worth $219,161,291. Corporate insiders own 18.20% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.